Chapter 13 Illicit drug use - WHO
The global burden of death and disability attributable to illicit drugs was first estimated by Donoghoe (1996), as part of the Global Burden of Disease (GBD) project (Murray and Lopez 1996). Donoghoe esti-mated that illicit drug use was responsible for 100000 deaths globally in 1990, the majority of which (62%) occurred in developing countries.
Download Chapter 13 Illicit drug use - WHO
Information
Domain:
Source:
Link to this page:
Documents from same domain
INVESTING IN HEALTH FOR ECONOMIC …
www.who.int2 INVESTING IN HEALTH FOR ECONOMIC DEVELOPMENT Report by the Mexican Commission on Macroeconomics and health 3 The …
WHO GOOD PRACTICES FOR PHARMACEUTICAL …
www.who.intworking document qas/09.297/rev.2 page 2 schedule for the proposed adoption process of document qas/09.297/rev.2: who good practices for pharmaceutical microbiology laboratories
NORMES ET STANDARDS EN INFRASTRUCTURES …
www.who.intnormes et standards en infrastructures et equipements du centre de sante et de promotion sociale, du centre medical avec antenne chirurgicale et du …
Heterotrophic Plate Count Measurement in …
www.who.intWorld Health Organization Sustainable Development and Healthy Environments Heterotrophic Plate Count Measurement in Drinking Water Safety Management
Annex 3 WHO good manufacturing practices for ...
www.who.int96 Introduction The fi rst WHO draft text on good manufacturing practices (GMP) was prepared in 1967 by a group of consultants at the request of the Twentieth
Annex 5 WHO good distribution practices for …
www.who.int236 1. Introduction Distribution is an important activity in the integrated supply-chain management of pharmaceutical products. Various people and entities are
Annex 2 WHO good practices for pharmaceutical …
www.who.int71 Introduction and scope of document Pharmaceutical microbiology laboratories may be involved in: — sterility testing; — detection, isolation, enumeration and identifi cation of microorganisms
LABORATORY BIOSAFETY MANUAL - WHO
www.who.intinterim guidelines WHO/CDS/CSR/LYO/2003.4 LABORATORY BIOSAFETY MANUAL SECOND EDITION (REVISED) WORLD HEALTH ORGANIZATION Geneva 2003
Mycobacteriology Laboratory Manual - WHO
www.who.intMycobacteriology Laboratory Manual ii Edita Pimkina, Infectious Diseases and Tuberculosis Hospital Affi liate of Public institution …
Laboratory Guidelines for enumerating CD4 T …
www.who.intSEA-HLM-392 Distribution: Limited Laboratory Guidelines for enumerating CD4 T Lymphocytes in the context of HIV/AIDS Regional Office for South-East Asia
Related documents
GBD PROFILE: INDIA
www.healthdata.orgThe Global Burden of Disease Study 2010 (GBD 2010) is a collaborative project of nearly 500 researchers in 50 countries led by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington. It is the largest systematic scientific effort in history to
Global Cancer Facts and Figures 4th Edition
www.cancer.orgThe Global Fight against Excess Body Weight 61 What Is the American Cancer Society Doing to Help Reduce Excess Body Weight and the Associated Cancer Burden? 62 References 63 The Global Fight against Cancer 67 Worldwide Tobacco Use 67 The Role of the American Cancer Society 68 References 69 Sources of Statistics 70 Incidence and Mortality Rates 70
NCD Burden of Disease - Centers for Disease Control and ...
www.cdc.govNCD Burden of Disease WHO Global Burden of Disease Study • WHO assessment of the global burden of disease, • Features comparisons between deaths, diseases and injuries by region, age, sex and country income • Provides projections of deaths and burden of disease by cause and region to the year 2030. 7
PRESS RELEASE N° 292 15 December 2020
www.iarc.who.intThe global cancer burden is estimated to have risen to 19.3 million new cases and 10.0 million deaths in 2020. 1. One in 5 people worldwide develop cancer during their lifetime and one in , 8 men and one in 11 women die from the disease.
Burden of disease: DALYs - World Health Organization
www.who.intThe global average burden of disease across all regions in 2004 was 237 DALYs per 1000 population, of which about 60% was due to premature death and 40% to non-fatal health outcomes. DALYs in Africa are at least two times higher than in any other region The contribution of premature death varied dra-